The question
Not “what drug should be given?” but a narrower and safer workflow question: should this case trigger a DPYD-focused review or testing discussion before treatment begins?
Flagship Case Study
DPYD review before fluoropyrimidine therapy, explained in plain English.
This example shows how QbitQure can support a more structured, accountable personalised-medicine workflow around a clinically meaningful question: should DPYD-related risk be reviewed before 5-FU or capecitabine treatment starts?
Why it is a good example
It is clinically recognizable, linked to accepted pharmacogenomic guidance, and well suited to a governed human-in-the-loop workflow.
Important boundary
This case study is informational and product-development focused. It is not treatment advice and should not be used as a prescribing instruction.
Why this use case matters
Fluoropyrimidine toxicity can be serious. A workflow that highlights whether DPYD-related risk should be reviewed or tested is a practical example of personalised medicine in action.
What QbitQure shows today
A governed pathway review can sit on top of structured case data, with provenance, sign-off, and final outcome recorded in the same workflow.
What it does not claim
This is not an autonomous chemotherapy prescribing or dose-adjustment engine. It is an early-stage workflow and review platform demonstration.
Workflow story
What QbitQure is trying to do in this scenario
The platform is not trying to make an ungoverned final decision. It is trying to make the review process cleaner: gather the case, preserve the source data, structure it, attach an explainable DPYD pathway review, and carry that through to sign-off and final outcome.
Step 1
Start with a case record
QbitQure begins with a structured case entry so the starting point is captured clearly and can be revisited later.
Step 2
Preserve provenance and structure the data
The original record is retained, then shaped into standards-aware clinical data so later review is traceable rather than opaque.
Step 3
Apply a bounded DPYD review prompt
The platform can then frame a pre-treatment fluoropyrimidine review around clearly stated factors, missing information, and whether genotype testing should be discussed.
Step 4
Keep the clinician in charge
Review state, GP sign-off, and final outcome remain explicit. The platform supports human judgement rather than replacing it.
The practical output
A review prompt, not a black-box answer.
In this workflow, QbitQure can surface a few bounded things: whether the case appears compatible with review, whether genotype information looks missing, whether a DPYD testing discussion may be warranted, and what sign-off state the case is in.
That means the value is not just the pathway logic itself. It is the combination of logic, provenance, governance, and outcome recording in one place.
Supporting references
QbitQure uses this example because it is easier to explain clearly than a vague “AI in healthcare” claim. It shows a real workflow shape with clear boundaries.
Collaboration
Interested in the platform direction behind this case study?
If you are interested in personalised medicine, translational health technology, pharmacogenomics workflows, or future computational medicine strategy, QbitQure is open to thoughtful discussion and collaboration.